Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sotera Health CoSHC -1.83%74 EV-to-EBITDA is 14.39 as of Jul. 21, 2026, which is 1% below its 10-year median of 14.48. GuruFocus rates SHC with a GF Score™ of 74/100 and a GF Value™ of $16.37 (Fairly Valued). The stock has 3 warning signs investors should review. Among 117 Medical Diagnostics & Research companies, Sotera Health Co ranks better than 50.43% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Sotera Health Co's enterprise value is $6,924 Mil.
Sotera Health Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $481 Mil. Therefore, Sotera Health Co's EV-to-EBITDA for today is 14.39.
The historical rank and industry rank for Sotera Health Co's EV-to-EBITDA or its related term are showing as below:
SHC'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -387.58 Med: 14.48 Max: 32.3
Current: 14.39
During the past 8 years, the highest EV-to-EBITDA of Sotera Health Co was 32.30. The lowest was -387.58. And the median was 14.48.
SHC's EV-to-EBITDA is ranked better than 50.43% of 117
companies
in the Medical Diagnostics & Research industry
Industry Median: 14.55
vs SHC: 14.39
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Sotera Health Co (NAS:SHC) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sotera Health Co's PE Ratio (TTM) for today is calculated as:
Sotera Health Co's share price for today is $17.42.
Sotera Health Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.410.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Sotera Health Co's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Sotera Health Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sotera Health Co EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Sotera Health Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Sotera Health Co's EV-to-EBITDA falls into.
Sotera Health Co's current Enterprise Value is $6,924 Mil.
Sotera Health Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $481 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sotera Health Co (SHC) has a EV-to-EBITDA of 14.39 as of Jul. 21, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Sotera Health Co. This is near median its historical median of 14.48. According to the industry distribution chart, Sotera Health Co ranks #58 out of 117 companies in the Medical Diagnostics & Research industry, placing it in the top 49.6%.
Is Sotera Health Co's EV-to-EBITDA too high?
Sotera Health Co's current EV-to-EBITDA of 14.39 is near median its 10-year median of 14.48. The Medical Diagnostics & Research industry median EV-to-EBITDA is 14.55. Sotera Health Co's value of 14.39 is 1.1% below this industry median. Based on the distribution chart, Sotera Health Co ranks #58 out of 117 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Sotera Health Co has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sotera Health Co's EV-to-EBITDA compare to VCYT and RDNT?
According to the Medical Diagnostics & Research industry distribution chart, Sotera Health Co ranks #58 out of 117 companies for EV-to-EBITDA. This puts Sotera Health Co in the upper half of its industry. The industry median EV-to-EBITDA is 14.55. Sotera Health Co's value of 14.39 is 1.1% below this benchmark. While the company's 10-year median is 14.48 vs. the industry median of 14.55, Sotera Health Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 14.55, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sotera Health Co's current EV-to-EBITDA of 14.39 is 1.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Sotera Health Co. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 14.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sotera Health Co's current EV-to-EBITDA is 14.39, which is near median its own 10-year median of 14.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sotera Health Co stock overvalued right now?
Based on GuruFocus' analysis, Sotera Health Co (SHC) is currently considered Fairly Valued. The stock's GF Value™ is $16.37, compared to a current price of $17.42 — trading 6.4% above its estimated fair value. The current EV-to-EBITDA is 14.39, which is near median its 10-year median of 14.48 and 1.1% below the Medical Diagnostics & Research industry median of 14.55. Sotera Health Co's overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Sotera Health Co (SHC), the current EV-to-EBITDA is 14.39 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sotera Health Co (SHC) Overvalued in 2026?
Based on GuruFocus' analysis, Sotera Health Co stock appears to be overvalued.
The current stock price of $17.42 is trading 6.4% above its estimated GF Value™ of $16.37.
GuruFocus considers Sotera Health Co to be Fairly Valued.
Key valuation signals for SHC:
EV-to-EBITDA: 14.39 (near median its 10-year median of 14.48)
GF Value™: $16.37 vs. price of $17.42 (6.4% above fair value)
Industry Position: 1.1% below the Medical Diagnostics & Research median (#58 of 117)
No single metric tells the full story. See the SHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical, and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three reportable segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment, which generates maximum revenue, provides outsourced terminal sterilization and irradiation services for medical devices, pharmaceuticals, food safety, and other application markets using three core technologies: gamma irradiation, EO processing, and E-beam irradiation. Geographically, the company generates maximum revenue from the United States, followed by Canada, Europe, and other regions.
74GF Score
Get the complete analysis for SHC
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHC has been successfully added to your 
